Yuji Miura

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy

Shiping Jiao, Sumit K. Subudhi, Ana M. Aparicio et al. · Cell · 2019 · 383 citations

Medicine, Immunology, Oncology +12

Association of Foxp3 regulatory gene expression with graft-versus-host disease

Yuji Miura, Christopher J. Thoburn, Emilie C. Bright et al. · Blood · 2004 · 314 citations · Full text

Life Sciences, Genetics, Molecular Biology +14

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities

Salahaldin A. Tahir, Jianjun Gao, Yuji Miura et al. · Proceedings of the National Academy of Sciences · 2019 · 241 citations · Full text

Life Sciences, Immunology, Oncology +17